Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo
出版年份 2013 全文链接
标题
Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo
作者
关键词
-
出版物
ACTA PHARMACOLOGICA SINICA
Volume 34, Issue 5, Pages 699-709
出版商
Springer Nature
发表日期
2013-04-08
DOI
10.1038/aps.2012.182
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway
- (2012) S Xu et al. LEUKEMIA
- Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts
- (2011) Meghan E. McGee-Lawrence et al. BONE
- A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
- (2011) S Vallet et al. LEUKEMIA
- Tumor–host cell interactions in the bone disease of myeloma
- (2010) Jessica A. Fowler et al. BONE
- Histone deacetylases in skeletal development and bone mass maintenance
- (2010) Meghan E. McGee-Lawrence et al. GENE
- The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss
- (2010) J. Pratap et al. MOLECULAR CANCER THERAPEUTICS
- Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells
- (2009) S. Lee et al. CELL PROLIFERATION
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- Vorinostat enhances the antimyeloma effects of melphalan and bortezomib
- (2009) Richard A. Campbell et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Epigenetic control of skull morphogenesis by histone deacetylase 8
- (2009) M. Haberland et al. GENES & DEVELOPMENT
- Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
- (2009) Evanthia Galanis et al. JOURNAL OF CLINICAL ONCOLOGY
- Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors
- (2009) M Garayoa et al. LEUKEMIA
- The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models
- (2009) S Deleu et al. LEUKEMIA
- Gene Therapy Using TRAIL-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells against Intracranial Glioma
- (2008) S. M. Kim et al. CANCER RESEARCH
- Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
- (2008) Paul Richardson et al. LEUKEMIA & LYMPHOMA
- Histone Deacetylase Inhibitors Promote Apoptosis and Senescence in Human Mesenchymal Stem Cells
- (2008) Giovanni Di Bernardo et al. STEM CELLS AND DEVELOPMENT
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started